Please login to the form below

Not currently logged in

Generex publishes Oral-Lyn study

Generex has published the results of a Oral-lyn study in the Diabetes Technology & Therapeutics journal covering new technology and products for the treatment, monitoring, diagnosis and prevention of diabetes

Generex Biotechnology, a US developer of buccal drug delivery for metabolic diseases, has published the results of a Oral-lyn study in Diabetes Technology & Therapeutics, a peer-reviewed journal covering new technology and products for the treatment, monitoring, diagnosis and prevention of diabetes.

Oral-lyn buccal spray uses Generex's proprietary drug delivery technology, RapidMist, which administers medications directly into the mouth as a metered-dose spray, for rapid absorption by the buccal mucosa.

The study, entitled 'Comparison of Oral Insulin Spray and Subcutaneous Regular Insulin at Mealtime in Type 1 Diabetes' was led by Dr Jaime Guevara-Aguirre, Dr Marco Guevara-Aguirre, Dr Jeannette Saavedra, Dr Gerald Bernstein and Dr Arlan L Rosenbloom.

The results of the study showed that regular insulin and Oral-lyn had similar glucodynamic effects in subjects with type 1 diabetes receiving a twice-daily insulin analogue as baseline therapy.

Monitoring and baseline corrections with additional snacks, subcutaneous regular insulin or Generex Oral-lyn puffs resulted in glycaemic control as assessed by individual daily glycaemic responses, while normal pre-prandial glycation decreased, but not significantly.

Dr Gerald Bernstein, Generex's vice-president of medical affairs and a co-author of the article, said: "This publication is significant in that it shows consistently and clearly that equivalent amounts of Generex Oral-lyn and injected regular insulin will yield comparable blood glucose control."

Generex launched Oral-Lyn in South America in 2005.

16th August 2007


Featured jobs

Subscribe to our email news alerts


Add my company
GCI Health

GCI Health London is a young, vibrant powerhouse in the European industry with a mission to redefine healthcare communications, starting...

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award
The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
Artificial Intelligence in Healthcare
Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...